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Objectives. The goal of this study was to compare the efficacy of
elective stent implantation and balloon angioplasty for new le-
sions in small coronary arteries.
Background. Palmaz-Schatz stents have been designed and
approved by the Food and Drug Administration for use in
coronary arteries with diameters >23.0 mm. The efficacy of elective
stent placement in smaller vessels has not been determined.
Methods. By quantitative coronary angiography, 331 patients in
the Stent Restenosis Study (STRESS) I–II were determined to
have a reference vessel <3.0 mm in diameter. Of these, 163
patients were randomly assigned to stenting (mean diameter
2.69 6 0.21 mm), and 168 patients were assigned to angioplasty
(mean diameter 2.64 6 0.24 mm). The primary end point was
restenosis, defined as >250% diameter stenosis at 6-month
follow-up angiography. Clinical event rates at 1 year were as-
sessed.
Results. Baseline clinical and angiographic characteristics were
similar in the two groups. Procedural success was achieved in
100% of patients assigned to stenting and in 92% of patients
assigned to angioplasty (p < 0.001). Abrupt closure within 30 days
occurred in 3.6% of patients in both groups. Compared with
angioplasty, stenting conferred a significantly larger postproce-
dural lumen diameter (2.26 vs. 1.80 mm, p < 0.001) and a larger
lumen at 6 months (1.54 vs. 1.27 mm, p < 0.001). Restenosis
(>250% diameter stenosis at follow-up) occurred in 34% of pa-
tients assigned to stenting and in 55% of patients assigned to
angioplasty (p < 0.001). At 1 year, event-free survival was
achieved in 78% of the stent group and in 67% of the angioplasty
group (p 5 0.019).
Conclusions. These findings suggest that elective stent place-
ment provides superior angiographic and clinical outcomes than
balloon angioplasty in vessels slightly smaller than 3 mm.
(J Am Coll Cardiol 1998;31:307–11)
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Palmaz-Schatz stents have been developed and approved by
the Food and Drug Administration (FDA) for use in large
coronary arteries with diameters $3.0 mm (1–3). The goal of
this Stent Restenosis Study (STRESS) substudy was to com-
pare the efficacy of elective stent implantation and balloon
angioplasty for new lesions in smaller vessels.
Methods
In the STRESS I–II trial, 598 patients with new lesions of
native coronary arteries were randomly assigned to either
elective placement of a Palmaz-Schatz stent or balloon angio-
plasty. Patient selection criteria, details of stent technique and
primary outcomes have been previously reported for the initial
410 patients (known as STRESS I) (2). The “STRESS II”
component of this trial represents the continuation of the
original STRESS trial under an investigational device exemp-
tion mandated by the FDA. The participating centers and
principal investigators are listed in the Appendix. The study
protocol was approved by the Institutional Review Board at
each site, and all patients gave written, informed consent.
Angiography was performed in paired orthogonal views before
and after intervention and at 6 months. Intracoronary nitro-
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glycerin (200 mg) was given before all angiographic assess-
ments. Quantitative angiographic analysis was performed in a
core laboratory at Jefferson Medical College using a validated
automatic edge-detection program (2,4–6). Vessel edges were
determined by the computerized algorithm, and lumen dimen-
sions were measured using the guiding catheter as a scaling
reference. The diameters of the normal-appearing segments,
proximal and distal to the lesions, were averaged to determine
the reference vessel diameter. The minimal lumen diameter
(MLD), reference diameter and percent diameter stenosis
were calculated as the mean values from orthogonal projec-
tions.
By quantitative analysis, 331 patients were determined to
have baseline reference vessels ,3.0 mm in diameter. In this
substudy analysis, the outcomes of stenting versus angioplasty
in these patients with small vessels were compared. The
primary angiographic end point of the trial was restenosis,
defined as $50% diameter stenosis at follow-up. The primary
clinical end point was defined as the occurrence of any of the
following events: death, myocardial infarction, coronary artery
bypass graft surgery or repeat angioplasty. Target lesion revas-
cularization was defined as repeat angioplasty or bypass sur-
gery performed because of restenosis.
Outcomes were analyzed by intention to treat. Results of
continuous data were expressed as the mean value 6 SD, and
differences between groups were assessed by two-tailed t tests.
Categoric data are presented as rates and comparisons made
by chi-square tests. One-year clinical event rates were calcu-
lated by Kaplan-Meier curves, with differences between the
treatment groups compared by log-rank tests. A p value ,0.05
was considered significant.
Results
One hundred sixty-three patients were assigned to stent
placement, and 168 patients were assigned to angioplasty.
Baseline clinical and lesion characteristics were similar in the
two groups (Table 1). The mean vessel size was 2.69 mm in the
stent group and 2.64 mm in the angioplasty group (p 5 NS).
Procedural success, defined as ,50% residual stenosis, was
achieved in 100% of patients assigned to stenting and in 92%
of patients assigned to angioplasty (p , 0.001). Abrupt reclo-
sure during the first 30 days was 3.6% in both groups. Vascular
complications requiring transfusion or surgical treatment were
also comparable (7.9% after stenting and 6.6% after angio-
plasty, p 5 NS).
Results of quantitative coronary angiography are shown in
Table 2. At baseline, there were no differences in stenosis
severity or MLD between the two groups. After the procedure,
a larger acute gain was achieved with stent placement, result-
ing in a larger mean MLD in the stent group (2.26 vs. 1.80 mm,
p , 0.001). Follow-up angiography was performed in 84% of
eligible patients. The stent group had a greater late loss in
MLD (0.75 vs. 0.56 mm, p 5 0.005) but greater overall net gain
(0.84 vs. 0.57 mm, p , 0.001), resulting in a larger MLD at 6
months (1.54 vs. 1.27 mm, p , 0.001). Cumulative frequency
curves of MLD at baseline, after the procedure and at
follow-up are plotted in Figure 1.
Abbreviations and Acronyms
MLD 5 minimal lumen diameter
STRESS 5 Stent Restenosis Study
Table 1. Baseline Clinical and Angiographic Characteristics*
Characteristic
Stent Group
(n 5 163)
Angioplasty Group
(n 5 168)
Age (yr) 59 6 10 61 6 11
Male 74% 68%
Hypertension 53% 52%
Hyperlipidemia 52% 57%
Current smoker 25% 20%
Diabetes 17% 16%
Unstable angina 56% 48%
MI within 6 wk 19% 25%
Vessel location
LAD 59% 58%
LCx 14% 10%
RCA 27% 32%
Vessel size (mm) 2.69 6 0.21 2.64 6 0.24
Range 2.05 2 2.99 1.93 2 2.99
Lesion length (mm) 8.9 6 3.0 8.5 6 2.5
Eccentric 58% 54%
Calcified 17% 18%
Ulcerated 18% 14%
Bend .45° 7% 14%
Thrombus
Definite 3% 1%
Possible 11% 10%
*p 5 NS for all comparisons. Data presented are mean value 6 SD or
percent of patients. LAD 5 left anterior descending coronary artery; LCx 5 left
circumflex coronary artery; MI 5 myocardial infarction; RCA 5 right coronary
artery.
Table 2. Results of Quantitative Coronary Angiography
Variable
Stent Group
(n 5 163)
Angioplasty Group
(n 5 168) p Value
% DS
Baseline 75 6 9 74 6 9 NS
After procedure 17 6 11 34 6 15 , 0.001
At 6 mo 44 6 19 54 6 20 , 0.001
MLD (mm)
Baseline 0.69 6 0.25 0.68 6 0.24 NS
After procedure 2.26 6 0.36 1.80 6 0.36 , 0.001
At 6 mo 1.54 6 0.54 1.27 6 0.53 , 0.001
Change in lumen
diameter (mm)
Acute gain 1.58 6 0.41 1.11 6 0.40 , 0.001
Late loss 0.75 6 0.55 0.56 6 0.55 0.005
Net gain 0.84 6 0.58 0.57 6 0.58 , 0.001
Data presented are mean value 6 SD. DS 5 diameter stenosis; MLD 5
minimal lumen diameter.
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The comparative effects of stenting and angioplasty as a
function of vessel size are shown in Figure 2. When compared
in arteries 2.75 to 2.99, 2.50 to 2.74 and #2.49 mm, stenting
conferred a significantly larger lumen at follow-up than did
balloon angioplasty. Six-month MLDs for stenting and angio-
plasty, respectively, were 1.60 versus 1.40 mm for 2.75 to
2.99 mm arteries, 1.55 versus 1.20 mm for 2.50 to 2.74 mm
arteries and 1.39 versus 1.14 mm for #2.49 mm arteries (all
p , 0.05). Thus, stenting conferred a significantly larger lumen
across all vessel sizes.
Restenosis rates are shown in Figure 3. For the entire
cohort of patients, restenosis was observed in 47 (34%) of 139
lesions in the stent group and in 66 (55%) of 121 lesions in the
angioplasty group (p , 0.001). Compared as a function of the
reference vessel size, the restenosis rates for stenting and
angioplasty, respectively, were 36% versus 50% in 2.75 to
2.99 mm arteries (p 5 0.125), 34% versus 59% in 2.50 to
2.74 mm arteries (p 5 0.024) and 30% versus 57% in
#2.49 mm arteries (p 5 0.028).
Rates of major cardiac events at 1 year are shown in Table
3. One-year survival was excellent in both groups: 99.4% in the
stent cohort and 98.2% in the angioplasty cohort (p 5 NS).
Repeat target lesion revascularization was significantly less
frequent in the stent group (16.1% vs. 26.6%, p 5 0.015).
Event-free survival (Fig. 4) was 77.9% in the stent group and
67.3% in the angioplasty group (p 5 0.019). Thus, stenting
conferred a 33% reduction in cardiac events compared with
balloon angioplasty.
Discussion
The complex, vexing problem of restenosis after balloon
angioplasty is influenced by a variety of clinical and anatomic
factors. One important anatomic factor is vessel size, because
the restenosis rate is inversely rated to the reference vessel
diameter (7,8). In the Multi-Hospital Eastern Atlantic Resten-
osis Trial (M-HEART) of 598 patients undergoing conven-
tional balloon angioplasty, Hirshfeld et al. (7) reported a
significantly higher restenosis rate of 44% in vessels ,2.9 mm
compared with a restenosis rate of 34% in vessels .2.9 mm. A
similar relation between vessel size and restenosis was ob-
served in the angioplasty arm of the STRESS trial (2). Accord-
ingly, interventions designed to ameliorate restenosis would
have a greater relative impact if applicable to smaller vessels.
Elective stenting in small vessels. The Palmaz-Schatz stent
was designed to reduce restenosis in large arteries with diam-
eters $3 mm. The present study suggests that elective stent
placement may be highly effective for smaller vessels. Com-
pared with balloon angioplasty, stent placement was associated
with a 38% relative reduction in restenosis and a 33% reduc-
tion in clinical events. These results have potentially far-
Table 3. Clinical Events at 1 Year
Event
Stent Group
(n 5 163)
Angioplasty Group
(n 5 168) p Value
Death 0.6 1.8 NS
MI 6.1 8.3 NS
CABG 6.7 11.9 NS
Repeat PTCA 16.6 21.4 NS
TLR 16.1 26.6 0.015
Any event 22.1 32.7 0.019
Data presented are percent of patients. CABG 5 coronary artery bypass
graft surgery; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal
coronary angioplasty; TLR 5 target lesion revascularization.
Figure 1. Cumulative frequency curves of MLD at baseline, immedi-
ately after the intervention and at follow-up. At baseline, there was no
difference between the stent and angioplasty groups. Immediately after
the procedure, a larger MLD was observed in the stent group. Six
months later, a larger lumen persisted in the stent group.
Figure 2. Minimal lumen diameter 6 months after the intervention as
a function of reference vessel size. Note that stenting (open bars)
conferred a significantly larger lumen irrespective of vessel size.
Hatched bars 5 percutaneous transluminal coronary angioplasty.
Figure 3. Restenosis rates after balloon angioplasty and coronary
stenting for all patients with small coronary arteries.
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reaching implications, because the routine use of stents in
small vessels would significantly enlarge the population of
patients who would be candidates for this breakthrough tech-
nology. Approximately one-half of coronary interventions in-
volve vessels ,3.0 mm in diameter, with 30% of procedures
performed in 2.5 to 2.9 mm vessels (9).
Stent thrombosis. The potential for stent thrombosis re-
mains an important concern for stents in small vessels. Previ-
ous studies of both the Palmaz-Schatz and Gianturco-Roubin
stents have demonstrated an inverse relation between vessel
size and the risk of stent thrombosis and early ischemic
complications (10,11). Although the present study was per-
formed using an anticoagulation regimen consisting of aspirin
and warfarin (Coumadin) without routine high pressure stent
deployment, the rate of abrupt reclosure was the same for the
stent and angioplasty groups. Nevertheless, the results of the
large French Multicenter Registry suggest that small vessel size
remains an important risk factor for stent thrombosis in the
current era of adjunctive aspirin and ticlopidine therapy with-
out Coumadin (12). In this prospective registry of 2,900
patients, thrombosis occurred in 10% of vessels treated with
stents sized #2.5 mm versus 1.5% of vessels treated with stents
sized $3.0 mm.
Study limitations. Although the current findings were
based on quantitative coronary analysis, the STRESS trial
protocol included only patients with vessels of ;3 mm (or
larger) in diameter by visual estimate. Accordingly, the trial
was not designed to test the efficacy of stenting in arteries that
the investigator subjectively perceived to be small. It should be
noted in this regard that the mean vessel size by quantitative
analysis in our study was .2.6 mm. However, even in the
cohort of patients with the smallest vessels (,2.5 mm), stenting
conferred a significant benefit on the 6-month angiographic
results. It is also important to note that the STRESS trial was
restricted to new focal lesions in the native circulation. These
results cannot be extrapolated to patient groups excluded from
the trial, including those with long, diffuse lesions or restenotic
lesions.
A final limitation of this study is the lack of cost-
effectiveness data. The routine use of stents in small vessel
intervention could potentially have significant economic con-
sequences. Procedural expenses would increase owing to the
additional costs associated with stent implantation. In contrast,
the reduction in repeat revascularization procedures would
provide a significant cost savings. Future studies will be needed
to assess the economic implications of elective stent placement
in the treatment of smaller coronary arteries.
Conclusions. This study suggests that elective stent place-
ment provides superior angiographic and clinical outcomes to
balloon angioplasty in vessels slightly smaller than 3 mm.
However, the study is limited by the retrospective nature of the
analysis. These promising results will be reassessed by the
STRESS IV trial, a prospective comparison of stent placement
and balloon angioplasty for small coronary arteries, using a
customized slotted tube stent designed for vessels 2.25 to
2.75 mm in diameter.
We thank Laraine Bartlett for help in manuscript preparation.
Appendix
STRESS I–II Principal Investigators and Sites
Sheldon Goldberg, MD, Michael P. Savage, MD, Thomas Jefferson University,
Philadelphia, Pennsylvania; Ian Penn, MD, Brendon Foley, MD, Victoria Hospi-
tal, London, Ontario, Canada; Michael Clemen, MD, Yale University, New Haven,
Connecticut; Donald Baim, MD, Beth Israel Hospital, Boston, Massachusetts;
Richard Stack, MD, James Zider, MD, Duke University, Durham, North Carolina;
Martin B. Leon, MD, Washington Hospital Center, Washington, D.C.; Jeffrey
Brinker, MD, Johns Hopkins Hospital, Baltimore, Maryland; David Fish, MD,
Texas Heart Institute, Houston, Texas; Richard A. Schatz, MD, Paul Teirstein,
MD, Scripps Clinic, La Jolla, California; Richard Heuser, MD, Arizona Heart
Institute, Phoenix, Arizona; Masakiyo Nobuyoshi, MD, Kokura Memorial Hospital,
Kitakyushu, Japan; Jeffrey Moses, MD, Lenox Hill Hospital, New York, New York;
Don Ricci, MD, Vancouver General Hospital, Vancouver, British Columbia,
Canada; John Hirshfeld, MD, Hospital of the University of Pennsylvania, Phila-
delphia, Pennsylvania; Antonio Columbo, MD, Yaron Almagor, MD, Centro
Cuore Columbus, Milan, Italy; David Almond, MD, Toronto General Hospital,
Toronto, Ontario, Canada; Steven Bailey, MD, University of Texas, San Antonio,
Texas; Stephen Ellis, MD, Cleveland Clinic Foundation, Cleveland, Ohio; Spencer
B. King III, MD, Emory University, Atlanta, Georgia; Charles Curry, MD, Florida
Heart Group, Orlando, Florida; Blair O’Neil, MD, Victoria General Hospital,
Halifax, Nova Scotia, Canada; Paul Overlie, MD, Cardiology Association of
Lubbock, Lubbock, Texas; David L. Fischman, MD, Randal Rake, BS, Diane
Rehmann, Core Laboratory, Thomas Jefferson University, Philadelphia, Pennsylva-
nia.
References
1. Serruys PW, Dejaegere P, Kiemeneij F, et al. A comparison of balloon-
expandable-stent implantation with balloon angioplasty in patients with
coronary artery disease. N Engl J Med 1994;331:489–95.
2. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of
coronary-stent placement and balloon angioplasty in the treatment of
coronary artery disease. N Engl J Med 1994;331:496–501.
3. Goldberg S, Savage M, Slota P, Fischman D. Coronary artery stents: a new
era in interventional cardiology. In: Topol EJ, editor. Textbook of Interven-
tional Cardiology. 2nd ed. Philadelphia: W.B. Saunders, 1996:291–302.
4. Mancini GBJ, Simon SB, McGillem MJ, LeFree MT, Friedman HZ, Vogel
RA. Automated quantitative coronary arteriography: morphologic physio-
logic validation in vivo of a rapid digital angiographic method. Circulation
1987;75:452–60.
5. Fischman DL, Savage MP, Ellis SG, et al. The Palmaz-Schatz stent. In:
Figure 4. Kaplan-Meier curves of event-free survival after angioplasty
and stenting at 1 year.
310 SAVAGE ET AL. JACC Vol. 31, No. 2
SMALL VESSEL STENTING February 1998:307–11
Reiber J, Serruys P, editors. Advances in Quantitative Coronary Angiogra-
phy. Dordrecht, The Netherlands: Kluwer Academic, 1993:553–66.
6. Savage MP, Fischman DL, Schatz RA, et al. Long-term angiographic and
clinical outcome after implantation of a balloon-expandable stent in the
native coronary circulation. J Am Coll Cardiol 1994;24:1207–12.
7. Hirshfeld JW, Schwartz JS, Jugo R, et al. Restenosis after coronary
angioplasty: a multivariate statistical model to relate lesion and procedure
variables to restenosis. J Am Coll Cardiol 1991;18:647–56.
8. Kuntz RE, Safian RD, Carrozza JP, Fishman RP, Mansour M, Baim DS. The
importance of acute luminal diameter in determining restenosis after
coronary atherectomy or stenting. Circulation 1992;86:1827–35.
9. Savage MP, Goldberg S, Hirshfeld JW, et al. Clinical and angiographic
determinants of primary coronary angioplasty success. J Am Coll Cardiol
1991;17:22–8.
10. Fischman DL, Savage MP, Goldberg S. Coronary stent thrombosis. In:
Hermann HC, Hirshfeld JW, editors. Clinical Use of the Palmaz-Schatz
Intracoronary Stent. Mount Kisco (NY): Futura, 1993:125–36.
11. Sutton JM, Ellis SG, Roubin GS, et al., for the Gianturco-Roubin Intracoro-
nary Stent Investigator Group. Major clinical events after coronary stenting.
Circulation 1994;89:1126–37.
12. Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implan-
tation without ultrasound guidance and with replacement of conventional
anticoagulation by antiplatelet therapy: 30-day clinical outcome of the
French Multicenter Registry. Circulation 1996;94:1519–27.
311JACC Vol. 31, No. 2 SAVAGE ET AL.
February 1998:307–11 SMALL VESSEL STENTING
